SLFN11 and head and neck squamous cell carcinoma: Patients with head and neck squamous cell carcinoma (HNSCC) have significant differences in their responses to cisplatin-based chemoradiotherapy (CRT), and SLFN11 expression levels have been revealed as a key prognostic factor that can predict treatment benefit.